Article Versions Notes

Varney L, Murtough S, Cotic M, Abidoph R, Chan L, Saadullah Khani N, Richards-Belle A, Richards-Brown M, Mills D, Panconesi D, et al. Effect of CYP1A2, CYP2D6, and CYP3A4 Variation on Antipsychotic Treatment Outcomes. Pharmaceuticals. 2025; 18(6):892. https://doi.org/10.3390/ph18060892

Varney, Lauren, Stephen Murtough, Marius Cotic, Rosemary Abidoph, Lian Chan, Noushin Saadullah Khani, Alvin Richards-Belle, Maria Richards-Brown, Daisy Mills, Daniele Panconesi, and et al. 2025. "Effect of CYP1A2, CYP2D6, and CYP3A4 Variation on Antipsychotic Treatment Outcomes" Pharmaceuticals 18, no. 6: 892. https://doi.org/10.3390/ph18060892

Varney, L., Murtough, S., Cotic, M., Abidoph, R., Chan, L., Saadullah Khani, N., Richards-Belle, A., Richards-Brown, M., Mills, D., Panconesi, D., Dawda, Y., Sharma, P., Shah, C., Secchi, A., Nilforooshan, R., Mudholkar, S., Murdoch, R., Molai, J., Griffiths, R., ... Bramon, E. (2025). Effect of CYP1A2, CYP2D6, and CYP3A4 Variation on Antipsychotic Treatment Outcomes. Pharmaceuticals, 18(6), 892. https://doi.org/10.3390/ph18060892